Esperion Therapeutics ESPR Product sales, net — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's product sales, net — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's product sales, net — total revenues?
- Esperion Therapeutics (ESPR) reported product sales, net — total revenues of $43.4M in Q1 2026.
- How has Esperion Therapeutics's product sales, net — total revenues changed year-over-year?
- Esperion Therapeutics's product sales, net — total revenues increased by 24.3% year-over-year, from $34.91M to $43.4M.
- What is the long-term trend for Esperion Therapeutics's product sales, net — total revenues?
- Over 4 years (2021 to 2025), Esperion Therapeutics's product sales, net — total revenues has grown at a 41.3% compound annual growth rate (CAGR), from $40.06M to $159.67M.
- What does product sales, net — total revenues mean?
- This metric represents the total revenue generated from the sale of pharmaceutical products after accounting for adjustments such as rebates, discounts, and returns. It serves as a primary indicator of market adoption and commercial success for the company's therapeutic portfolio. Tracking this figure allows investors to evaluate the underlying growth trajectory of the core business independent of licensing or collaboration income.